PM534

PM534 is a novel synthetic small molecule derived from structure–activity relationship studies on the natural marine compound PM742. It functions as a microtubule-destabilizing agent by binding to the colchicine site of tubulin, covering four out of five centers of the pharmacophore model for this binding domain. This optimized interaction results in high nanomolar affinity and an unusually long retention time at its target, leading to potent antitumor activity. PM534 efficiently overcomes two major resistance mechanisms in cancer cells: detoxification pump (P-gp) overexpression and βIII-tubulin isotype upregulation, both common in aggressive and treatment-refractory cancers. In preclinical models, it has demonstrated strong inhibition of tumor growth and antiangiogenic effects by preventing blood vessel formation necessary for tumor progression. The drug is currently being evaluated in Phase 1 clinical trials for advanced solid tumors[1][2][3][4][5][6][8][10].